Keytruda with or without Sac-TMT for advanced squamous lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests the combination of pembrolizumab (Keytruda) with or without a new drug, sacituzumab tirumotecan (Sac-TMT), as initial treatment for advanced squamous non-small cell lung cancer. It aims to see if adding Sac-TMT after initial treatment helps keep cancer under control longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage IV (advanced) squamous non-small cell lung cancer.
- You should not have had prior chemotherapy or immunotherapy for lung cancer that has spread.
- You must be in generally good health (able to care for yourself) and have a life expectancy of at least 3 months.
- You must not have had previous treatment with TROP2-directed therapies or topoisomerase I inhibitors.
- You must not have active brain metastases, uncontrolled eye diseases, inflammatory bowel disease, or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a new drug (sacituzumab tirumotecan) to pembrolizumab for people with non-small cell lung cancer that did not completely disappear after initial treatment and surgery. The goal is to see if the combination works better than pembrolizumab alone.
This trial tests a new combination of drugs (Keytruda with or without chemotherapy) to see if it works better for advanced lung cancer. It's for people who haven't had immunotherapy or chemotherapy for their cancer that has spread.
This trial tests a combination of two drugs, Sac-TMT and bevacizumab, as a second treatment option for people with advanced non-squamous non-small cell lung cancer whose cancer has gotten worse after initial chemotherapy and immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study compares a new combination of two immunotherapy drugs (sacituzumab tirumotecan plus pembrolizumab) versus pembrolizumab alone for people with advanced non-small cell lung cancer that has a high PD-L1 level (≥50%) and has not been treated yet. The goal is to see if the combination works better than the standard single immunotherapy.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.